Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Future drug discovery in renin-angiotensin-aldosterone system intervention
María Tamargo, Juan Tamargo
Expert Opinion on Drug Discovery (2017), pp. 1-22
Closed Access | Times Cited: 34

Showing 1-25 of 34 citing articles:

The renin-angiotensin-aldosterone system and its therapeutic targets
Katrina M. Mirabito Colafella, Dominique M. Bovée, A.H. Jan Danser
Experimental Eye Research (2019) Vol. 186, pp. 107680-107680
Closed Access | Times Cited: 154
A New Perspective on the Renin-Angiotensin System
Adrian Martyniak, Przemysław Tomasik
Diagnostics (2022) Vol. 13, Iss. 1, pp. 16-16
Open Access | Times Cited: 52
Multifunctional angiotensin converting enzyme 2, the SARS-CoV-2 entry receptor, and critical appraisal of its role in acute lung injury
Murat Öz, Dietrich E. Lorke
Biomedicine & Pharmacotherapy (2021) Vol. 136, pp. 111193-111193
Open Access | Times Cited: 53
Renin-angiotensin system: The underlying mechanisms and promising therapeutical target for depression and anxiety
Sizhu Gong, Fang Deng
Frontiers in Immunology (2023) Vol. 13
Open Access | Times Cited: 18
Pathways of hepatic and renal damage through non‐classical activation of the renin‐angiotensin system in chronic liver disease
G. Sansoè, Manuela Aragno, Florence Wong
Liver International (2019) Vol. 40, Iss. 1, pp. 18-31
Open Access | Times Cited: 51
Gentiopicroside Ameliorates Diabetic Renal Tubulointerstitial Fibrosis via Inhibiting the AT1R/CK2/NF-κB Pathway
Zhanchi Xu, Meng Zhang, Yu Wang, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 23
Plasma and tissue angiotensin‐converting enzyme 2 activity and plasma equilibrium concentrations of angiotensin peptides in dogs with heart disease
Éva Larouche‐Lebel, Kerry A. Loughran, Mark A. Oyama, et al.
Journal of Veterinary Internal Medicine (2019) Vol. 33, Iss. 4, pp. 1571-1584
Open Access | Times Cited: 31
Angiotensin Receptor Blockers Are Not Just for Hypertension Anymore
Juan M. Saavedra
Physiology (2021) Vol. 36, Iss. 3, pp. 160-173
Closed Access | Times Cited: 27
Renal Denervation: A New Therapy for Resistant Hypertension
Dhaval Trivedi, Manish A. Parikh, Gioia Turitto, et al.
Cardiology in Review (2025)
Closed Access
Current understanding of the link between angiotensin-converting enzyme and pain perception
Kiran D. Bhilare, Prakashkumar Dobariya, Filip Hanak, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 9, pp. 104089-104089
Closed Access | Times Cited: 3
Advances in understanding the role of angiotensin-regulated proteins in kidney diseases
Ana B. Sanz, Adrián M. Ramos, María José Soler, et al.
Expert Review of Proteomics (2018) Vol. 16, Iss. 1, pp. 77-92
Closed Access | Times Cited: 24
Targeting the renin angiotensin system for the treatment of anxiety and depression
Sophocles Chrissobolis, Anh Luu, R. Waldschmidt, et al.
Pharmacology Biochemistry and Behavior (2020) Vol. 199, pp. 173063-173063
Closed Access | Times Cited: 22
New drugs in preclinical and early stage clinical development in the treatment of heart failure
Juan Tamargo, Ricardo Caballero, Eva Delpón
Expert Opinion on Investigational Drugs (2018) Vol. 28, Iss. 1, pp. 51-71
Closed Access | Times Cited: 22
Host–Guest Interactions between Candesartan and Its Prodrug Candesartan Cilexetil in Complex with 2-Hydroxypropyl-β-cyclodextrin: On the Biological Potency for Angiotensin II Antagonism
Dimitrios Ntountaniotis, Ioannis Andreadelis, Tahsin F. Kellici, et al.
Molecular Pharmaceutics (2019) Vol. 16, Iss. 3, pp. 1255-1271
Closed Access | Times Cited: 22
Combination of Chymostatin and Aliskiren attenuates ER stress induced by lipid overload in kidney tubular cells
Miaojuan Qiu, Suchun Li, Lizi Jin, et al.
Lipids in Health and Disease (2018) Vol. 17, Iss. 1
Open Access | Times Cited: 15
Novel 18F-Labeled PET Imaging Agent FV45 Targeting the Renin–Angiotensin System
Xinyu Chen, Mitsuru Hirano, Rudolf A. Werner, et al.
ACS Omega (2018) Vol. 3, Iss. 9, pp. 10460-10470
Open Access | Times Cited: 12
Myocardial Cell Signaling During the Transition to Heart Failure
Matthew R. Zeglinski, Adel Rezaei Moghadam, Sudharsana Rao Ande, et al.
Comprehensive physiology (2018), pp. 75-125
Closed Access | Times Cited: 12
Interference With the Renin–Angiotensin System (RAS): Classical Inhibitors and Novel Approaches
Katrina M. Mirabito Colafella, Estrellita Uijl, A.H. Jan Danser
Elsevier eBooks (2018), pp. 523-530
Closed Access | Times Cited: 9
The Mechanisms of Actions of Aldosterone and its Antagonists in Cardiovascular Disease
Panteleimon Pantelidis, Michail Sideris, Margus Viigimaa, et al.
Current Pharmaceutical Design (2019) Vol. 24, Iss. 46, pp. 5491-5499
Closed Access | Times Cited: 9
Advancing the Therapeutic Efficacy of Bioactive Molecules by Delivery Vehicle Platforms
Antonis D. Tsiailanis, Andreas G. Tzakos, Thomas Mavromoustakos
Current Medicinal Chemistry (2020) Vol. 28, Iss. 14, pp. 2697-2706
Closed Access | Times Cited: 9
The Embryonic Chick Femur Organotypic Model as a Tool to Analyze the Angiotensin II Axis on Bone Tissue
Thais Francini Garbieri, Víctor Martín, Carlos Ferreira Santos, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 5, pp. 469-469
Open Access | Times Cited: 8
Deciphering bioactive compounds of complex natural products by tandem mass spectral molecular networking combined with an aggregation-induced emission based probe
Zhenzhong Yang, ­Jun Li­, Xuechun Chen, et al.
Journal of Pharmaceutical Analysis (2020) Vol. 12, Iss. 1, pp. 129-135
Open Access | Times Cited: 7
N-Aryl-7-hydroxy-5-oxo-2,3-dihydro-1H,5H-pyrido-[3,2,1-ij]quinoline-6-carboxamides. The Synthesis and Effects on Urinary Output
И. В. Украинец, Л. В. Сидоренко, M. Yu. Golik, et al.
Scientia Pharmaceutica (2018) Vol. 86, Iss. 2, pp. 12-12
Open Access | Times Cited: 5
Future Anti-aldosterone Agents
Kyriakos Dimitriadis, Constantinos Tsioufis, Panayotis Iliakis, et al.
Current Pharmaceutical Design (2019) Vol. 24, Iss. 46, pp. 5548-5554
Closed Access | Times Cited: 5
Transforming Non-Selective Angiotensin-Converting Enzyme Inhibitors in C- and N-domain Selective Inhibitors by Using Computational Tools
Sergio Alfaro, Carlos Navarro‐Retamal, Julio Caballero
Mini-Reviews in Medicinal Chemistry (2019) Vol. 20, Iss. 14, pp. 1436-1446
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top